West Pharmaceutical Services, Inc. filings document the regulatory record of a Pennsylvania operating company that supplies injectable drug containment, delivery and contract-manufacturing services. Its Form 8-K reports commonly furnish quarterly and full-year operating results, financial presentation materials and Regulation FD disclosures tied to earnings releases.
West's proxy and annual meeting filings cover board elections, executive compensation, advisory votes and shareholder voting results for its common stock. Other current reports record executive-transition matters and related governance disclosures, while exhibit filings provide the formal press releases, presentations and Inline XBRL cover-page data attached to those events.
West Pharmaceutical Services President and CEO Eric Mark Green reported several equity-related transactions. On February 17, 2026, he acquired 4,418.771 shares of common stock as a grant. On February 18, 2026, 1,318.810 restricted stock units, stemming from 2023–2025 performance stock units, converted into common stock on a one-for-one basis. To cover tax obligations, he disposed of 1,305.382 shares at $243.19 and 573.551 shares at $248.26. Following these transactions, he directly owned 175,160.6588 common shares and indirectly held 257.375 shares through a Non-Qualified Deferred Compensation Plan.
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite reported multiple equity transactions. On February 17, 2026, she acquired 441.957 shares of common stock through a grant or award and had 150.443 shares withheld to cover tax obligations. On February 18, 2026, she exercised 135.491 restricted stock units, converting them into the same number of common shares, with 35.757 shares withheld for taxes at prices of $243.1900 and $248.2600 per share, respectively. After these direct transactions, she held 17,374.4904 common shares directly and 4,962.0000 shares indirectly through a Non-Qualified Deferred Compensation Plan. Footnotes state that performance stock units from the 2023-2025 period vested and that restricted stock units convert into common stock on a one-for-one basis.
West Pharmaceutical Services, Inc. filed its annual report detailing a global injectable drug-packaging and delivery business organized into Proprietary Products and Contract-Manufactured Products. Sales outside the U.S. represented 56.7% of 2025 consolidated net sales, underscoring its international exposure.
The company highlights concentration risk: its ten largest customers made up 47.6% of 2025 net sales, and one customer contributed 15.8% or $485.9 million. As of June 30, 2025, non‑affiliate market value was about $15.7 billion, and there were 72,021,491 shares outstanding on January 29, 2026.
West employed about 10,800 people as of December 31, 2025 and continued quarterly dividends, raising the payout to $0.22 per share in the fourth quarter of 2025. The filing discusses supply chain, inflation, GLP‑1 exposure, cybersecurity, climate and regulatory risks, and notes a definitive agreement to sell the SmartDose 3.5mL On‑Body Delivery System rights and facilities to AbbVie.
West Pharmaceutical Services SVP & CFO Robert W. McMahon reported equity award activity on February 11, 2026. He converted 4,230.525 restricted stock units into the same number of common shares at an exercise price of $0.
To cover tax obligations, 1,250.034 common shares were withheld at $246.16 per share, leaving 2,980.491 common shares held directly after the transaction. He also reported 8,462.052 restricted stock units remaining outstanding following these events.
West Pharmaceutical Services, Inc. reported steady growth for the fourth quarter and full year 2025 and issued 2026 guidance. Fourth-quarter net sales were $805.0 million, up 7.5% with 3.3% organic growth, and adjusted diluted EPS rose 12.1% to $2.04.
For 2025, net sales reached $3.074 billion, increasing 6.3% with 4.3% organic growth, while adjusted diluted EPS grew 8.0% to $7.29. Operating cash flow was $754.8 million and free cash flow rose 69.6% to $468.9 million, reflecting lower capital spending.
Management expects 2026 net sales between $3.215 billion and $3.275 billion, implying 5% to 7% organic growth, and adjusted diluted EPS between $7.85 and $8.20, or 7.7% to 12.5% growth. Guidance assumes a mid-2026 close for the SmartDose 3.5mL sale to AbbVie.
West Pharmaceutical Services director reports equity awards and holdings. Director Janet Haugen reported beneficial ownership of 1,320.262 shares of West Pharmaceutical common stock, which includes 1,071 restricted stock units and related dividend equivalents that will vest in full on the date of the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors.
She also acquired 46 phantom stock units on 12/31/2025, each linked to one share of common stock at a reference price of $275.14, increasing her total phantom stock units to 208.3. These phantom units are to be settled in shares of stock when she terminates service as a director.
West Pharmaceutical Services executive Norman D. Finch, Jr., who serves as SVP, General Counsel & Corporate Secretary, reported equity awards in the company’s stock. On December 8, 2025, he received 192 restricted stock units, each representing a right to receive one share of common stock. This award is scheduled to vest in four equal installments beginning December 8, 2026, providing a staggered long-term incentive.
On the same date, Finch also received a stock option covering 459 shares of West Pharmaceutical common stock at an exercise price of $269.08 per share, with an expiration date of December 8, 2035. Both the RSUs and the option are reported as directly owned and reflect standard equity-based compensation for a senior officer.
West Pharmaceutical Services reported insider equity holdings for a senior executive. The reporting person is an officer of the company, serving as SVP, General Counsel and Corporate Secretary. The filing shows derivative holdings including 192 restricted stock units tied to West Pharmaceutical common stock, which vest in four equal installments beginning on December 8, 2026. It also discloses a stock option covering 459 shares of common stock with an exercise price of $269.08 per share and an expiration date of December 8, 2035. These details outline part of the executive’s long-term, equity-based compensation linked to the company’s share performance.
West Pharmaceutical Services (WST): Schedule 13G/A filed by The Vanguard Group
The Vanguard Group reported beneficial ownership of 9,704,948 shares of WST common stock, representing 13.49% of the class as of 09/30/2025. Vanguard reported 0 shares with sole voting power and 422,261 with shared voting power. It reported 9,018,715 shares with sole dispositive power and 686,233 with shared dispositive power.
Vanguard states the securities are held in the ordinary course and not to influence control. Its clients have the right to receive dividends or sale proceeds, and no single client’s interest exceeds 5%.
West Pharmaceutical Services (WST) reported higher Q3 results. Net sales rose to $804.6 million from $746.9 million, driven primarily by the Proprietary Products segment ($647.5 million vs. $601.4 million). Gross profit increased to $294.3 million, and operating profit was $167.6 million. Net income was $140.0 million, with diluted EPS of $1.92, up from $1.85.
For the first nine months, net sales reached $2,269.1 million versus $2,144.4 million. Operating cash flow was strong at $503.7 million, while capital expenditures were $209.8 million. Cash and cash equivalents were $628.5 million at September 30, 2025, and long-term debt stood at $202.7 million, with $497.7 million available under the $500 million revolver. The company spent $134.0 million on share repurchases year‑to‑date and paid dividends of $45.4 million.
Product mix remained favorable: High‑Value Product components represented 48% of Q3 sales. The company recorded $21.9 million of restructuring and related charges year‑to‑date under a 2025 plan that targets approximately $30–$32 million of total charges and annualized savings of $35–$40 million. The effective tax rate was 19.8% in Q3 and 20.1% year‑to‑date.